Here’s a roundup of companies announcing new distribution deals.
Metamark Genetics Inc. entered into a global licensing agreement with HistoRx Inc. for its Aqua technology.
The Naples, Fla.-based firm, which has operations in Cambridge, Mass., has been developing its diagnostic assays for cancer analysis using the HistoRx protein biomarker diagnostic for several years, according to the company.
HistoRx Inc. has landed a big boost for its cancer prognosis methods from the U.S. Patent and Trademark Office, as the New Haven, Conn.-based diagnostics firm was granted an exclusive license to its cancer treatment patent.
HistoRx Inc., a cancer therapy diagnostics firm based in New Haven, won a $1.5 million loan from Connecticut’s quasi-public life sciences initiative.
HistoRx is developing what it calls AQUA, technology designed to assess the potential effectiveness of cancer drugs and predict patients’ responses to the treatments. The system uses fluorescence-based image analysis and automated microscopy to measure protein molecules. Connecticut Innovations, the quasi-public equivalent of the Mass. Life Sciences Center, is loaning the company $1.5 million to build out laboratory space and buy equipment.